Zynex Inc ZYXI
We take great care to ensure that the data presented and summarized in this overview for ZYNEX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZYXI
View all-
Black Rock Inc. New York, NY1.24MShares$10 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.18MShares$9.51 Million0.0% of portfolio
-
Hotchkis & Wiley Capital Management LLC Los Angeles, CA746KShares$6.02 Million0.02% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT490KShares$3.95 Million0.24% of portfolio
-
Geode Capital Management, LLC Boston, MA426KShares$3.43 Million0.0% of portfolio
-
State Street Corp Boston, MA378KShares$3.05 Million0.0% of portfolio
-
Bridge City Capital, LLC Lake Oswego, OR295KShares$2.38 Million0.67% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA258KShares$2.08 Million0.0% of portfolio
-
Royce & Associates LP257KShares$2.08 Million0.02% of portfolio
-
Rice Hall James & Associates, LLC231KShares$1.86 Million0.11% of portfolio
Latest Institutional Activity in ZYXI
Top Purchases
Top Sells
About ZYXI
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Insider Transactions at ZYXI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 05
2024
|
Daniel J Moorhead CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,879
-12.06%
|
$34,153
$7.94 P/Share
|
Dec 05
2024
|
Daniel J Moorhead CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+6.99%
|
-
|
Dec 02
2024
|
Daniel J Moorhead CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-22.13%
|
$80,000
$8.08 P/Share
|
Nov 14
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.09 P/Share
|
Nov 13
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.37 P/Share
|
Nov 12
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$18,000
$9.24 P/Share
|
Nov 11
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$18,000
$9.09 P/Share
|
Nov 08
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.77 P/Share
|
Nov 07
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$18,000
$9.17 P/Share
|
Nov 06
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.82 P/Share
|
Nov 05
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.05 P/Share
|
Nov 04
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.67 P/Share
|
Nov 01
2024
|
Daniel J Moorhead CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-18.22%
|
$80,000
$8.59 P/Share
|
Nov 01
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.63 P/Share
|
Oct 31
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.82 P/Share
|
Oct 30
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
SELL
Open market or private sale
|
Direct |
2,000
-0.01%
|
$16,000
$8.92 P/Share
|
Oct 29
2024
|
Anna Lucsok CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,764
+3.6%
|
-
|
Oct 29
2024
|
Daniel J Moorhead CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,912
+8.47%
|
-
|
Oct 29
2024
|
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
6,912
+24.59%
|
-
|
Oct 27
2024
|
Anna Lucsok CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,323
-9.54%
|
$20,907
$9.12 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 99.4K shares |
---|---|
Open market or private purchase | 7K shares |
Payment of exercise price or tax liability | 38.9K shares |
---|---|
Open market or private sale | 83.9K shares |